BusinessSecond CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque PsoriasisBy Nasdaq OMXDec 8, 2016, 7:00 AM UTC
BusinessGalectin Therapeutics Announces Positive New Psoriasis and Atopic Dermatitis Clinical Data, Seeking Strategic Partnerships for Therapy of Severe Skin DiseasesBy Nasdaq OMXNov 10, 2016, 1:00 PM UTC
BusinessDermira Reports Third Quarter 2016 Financial Results and Provides Corporate UpdateBy Nasdaq OMXNov 7, 2016, 9:08 PM UTC
BusinessDermira Presents Data from DRM01 Phase 2b Clinical Program at Annual Meeting for DermatologistsBy Nasdaq OMXOct 21, 2016, 11:30 AM UTC
BusinessDermira to Present Data from DRM01 and DRM04 Clinical Programs at Fall Clinical Dermatology ConferenceBy Nasdaq OMXOct 13, 2016, 11:31 AM UTC
BusinessGalectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic SteatohepatitisBy Nasdaq OMXOct 7, 2016, 12:30 PM UTC
BusinessCIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque PsoriasisBy Nasdaq OMXOct 3, 2016, 6:00 AM UTC
